Investments
60Portfolio Exits
3About Delian Capital
Delian Capital is an investment management agency focused on the transformation and upgrading of China's traditional industries, in a mature or high-growth stage of investment opportunities for small and medium private enterprises. The firm is mainly concerned on areas including new materials, new energy, resource comprehensive utilization based environmental protection, high-end manufacturing, medical health, TMT, and other fields.
Delian Capital Headquarters Location
Suite 1907, Office Tower E1 Oriental Plaza, No.1East
Beijing, Beijing,
China
+86 10 8518 8998 825
Latest Delian Capital News
Sep 30, 2021
Hangzhou, CHINA HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the world’s most debilitating diseases, today announced that it has appointed Guobao Zhao as Senior Vice President responsible for business development and corporate strategy. Mr. Zhao has extensive experience working in senior management roles. Before joining the Company, Mr. Zhao was Senior Vice President at Delian Capital where he has led Delian’s investments in Amunix, Apexigen, and MicuRx. In addition, Mr.Zhao also represents Delian as a Board member or observer on OnKure, Hummingbird Bioscience, and Chance Pharmaceuticals. Prior to joining Delian Capital, Mr. Zhao served as an R&D Manager at CASI Pharmaceuticals, a publicly traded company listed on Nasdaq. “Guobao is a seasoned leader with significant experience in corporate strategy and business development, which is highly valuable to us as we implement our long-term corporate strategy,” said Dr. Donghao Chen, founder and CEO of Chance Pharmaceuticals. “We believe Guobao’s extensive experience in investing in life science companies and business development skills should help Chance strengthen channel partnerships, develop strategic alliances, and expand our international sales presence.” Mr. Zhao commented, "It has been a tremendous honor to join Chance and serve as Senior Vice President. I very much look forward to working with Chance's management team to solidify its leadership position in the inhalation therapy area. I am confident that Chance is well positioned to capture the market opportunities and achieve rapid further growth." About Hangzhou Chance Pharmaceuticals Co. Ltd. Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world’s most debilitating diseases. For more information, please visit http://www.chancepharmaceuticals.com . Contact Information:
Delian Capital Investments
60 Investments
Delian Capital has made 60 investments. Their latest investment was in Trinova as part of their Series B - II on August 8, 2022.
Delian Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/2/2022 | Series B - II | Trinova | No | 3 | ||
6/10/2022 | Series A | DOiTECH | Yes | 1 | ||
2/8/2022 | Series A - II | AIForceTech | No | 5 | ||
1/7/2022 | Series A | |||||
12/27/2021 | Series A |
Date | 8/2/2022 | 6/10/2022 | 2/8/2022 | 1/7/2022 | 12/27/2021 |
---|---|---|---|---|---|
Round | Series B - II | Series A | Series A - II | Series A | Series A |
Company | Trinova | DOiTECH | AIForceTech | ||
Amount | |||||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 3 | 1 | 5 |
Delian Capital Portfolio Exits
3 Portfolio Exits
Delian Capital has 3 portfolio exits. Their latest portfolio exit was MicuRx Pharmaceuticals on August 05, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
8/5/2022 | IPO | Public | 1 | ||
Date | 8/5/2022 | ||
---|---|---|---|
Exit | IPO | ||
Companies | |||
Valuation | |||
Acquirer | Public | ||
Sources | 1 |
Delian Capital Team
1 Team Member
Delian Capital has 1 team member, including former Senior Vice President, Guobao Zhao.
Name | Work History | Title | Status |
---|---|---|---|
Guobao Zhao | JD Capital Management, CASI Pharmaceuticals, and BioDuro | Senior Vice President | Former |
Name | Guobao Zhao |
---|---|
Work History | JD Capital Management, CASI Pharmaceuticals, and BioDuro |
Title | Senior Vice President |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.